+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 154 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
A

Actively Recruiting

Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
P

Actively Recruiting

Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.

Age: 12Years +All GendersPhase 1Phase 2
104 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations

1-10 of 154

1